Benign prostatic hyperplasia treatment method and device

• US 8,876,810 B2
• Filed: 03/06/2007
• Issued: 11/04/2014
• Est. Priority Date: 03/20/2006
• Status: Expired due to Fees

• Current Assignee: Biolitec Unternehmensbeteiligungs II AG
• Original Assignee: Biolitec Pharma Marketing Ltd.
• Inventors: Neuberger, Wolfgang
• Primary Examiner(s): Crandall, Lynsey
• Application Number:
  US11/714,370
• Publication Number:
  US 20070219601A1
• Time in Patent Office: 2,800 Days
• Field of Search: 128/898, 606 2- 19
• US Class Current: 606/16
• CPC Class Codes: A61B 18/24 with a catheter A61B18/26, A61B18/28 take precedence
• CPC Class Codes: A61B 2017/00274 Prostate operation, e.g. prostatectomy, turp, bhp treatment
• CPC Class Codes: A61B 2018/00547 Prostate
• CPC Class Codes: A61B 2018/2005 with beam delivery through an interstitially insertable device, e.g. needle
• CPC Class Codes: A61B 2018/207 mixing two wavelengths
• CPC Class Codes: A61B 2018/2272 with reflective or refractive surfaces for deflecting the beam A61B2018/2261, A61B2018/2266 take precedence
• CPC Class Codes: A61N 2005/0659 infrared

Abstract

A device and method are provided which achieve tissue ablation as well as tissue coagulation substantially simultaneously during the treatment of BPH by utilizing at least two wavelengths of light. The device and method improve urinary flow and minimize post-treatment blood loss and edema while maintaining a nearly blood-free operating field during treatment by irradiating substantially simultaneously with at least two different wavelengths of light. According to the present invention, tissue ablation is affected by having one wavelength that is highly absorbed in the prostatic tissue while another less highly absorbed wavelength coagulates surrounding tissues while maintaining minimal thermal damage to surrounding tissue. In a preferred embodiment the highly absorbed wavelength is about 1460 nm and the less absorbed by water but with some significant hemoglobin absorption is about 980 nm. This combination aids the patient by reducing blood loss and edema. It can aid the practitioner, especially where imaging is employed, by maintaining a substantially blood-free area during treatment. The present device and method is used in conjunction with optical fibers including side emitting optical fibers to provide a practical, minimally invasive treatment of enlarged prostates.

Claims

1. A method of treating benign prostatic hyperplasia of a prostate comprising the steps of:

providing a medical laser device having two laser sources therein, said laser sources emitting two wavelengths of radiation;

selecting a combination of said wavelengths to effect a desired treatment of selected prostatic tissue, wherein the first wavelength provides a coagulating effecting the prostatic tissue, and the second wavelength causes ablation of prostatic tissue;

delivering said radiation to said selective prostatic tissue by means of an optical fiber having a fiber core and at least one cladding layer;

positioning an distal end of said optical fiber system in or near said selected prostatic tissue; and

irradiating said selected prostate tissue of said prostate with said radiation, wherein said first wavelength is transmitted through the at least one cladding layer and said second wavelength is transmitted through said fiber core, wherein said first wavelength transmitted through the at least one cladding layer is shorter than said second wavelength transmitted through said fiber core.

2. A method of treating benign prostatic hyperplasia according to claim 1, wherein said first and said second wavelengths of said radiation are substantially simultaneously delivered.

3. A method of treating benign prostatic hyperplasia according to claim 1, wherein said step of irradiating said selected prostatic tissue includes delivering the first and second wavelengths in a pattern of pulse and energy densities.

4. A method of treating benign prostatic hyperplasia according to claim 1, wherein said first wavelength is 980 (±

20) nm and said second wavelength is 1460 (±

60) nm.

5. A method of treating benign prostatic hyperplasia according to claim 1 wherein the optical fiber has a distal end selected from the group consisting of a bare fiber, a capped fiber, and a fiber with a shape end.

6. A method of treating benign prostatic hyperplasia according to claim 1 wherein the optical fiber has a distal end that provides side-firing irradiation of said prostatic tissue.

7. A method of treating benign prostatic hyperplasia according to claim 1, wherein said second wavelength of radiation irradiating said selected prostate tissue forms an inner cone surrounded by an outer cone formed by said first wavelength of radiation irradiating said selected prostate tissue.